[Endocrine disorders after combined chemoradiotherapy in Hodgkin Lymphoma survivors].
Journal
Problemy endokrinologii
ISSN: 2308-1430
Titre abrégé: Probl Endokrinol (Mosk)
Pays: Russia (Federation)
ID NLM: 0140673
Informations de publication
Date de publication:
11 May 2023
11 May 2023
Historique:
received:
05
05
2022
accepted:
29
12
2022
revised:
02
12
2022
medline:
17
7
2023
pubmed:
14
7
2023
entrez:
14
7
2023
Statut:
epublish
Résumé
Hodgkin's lymphoma (HL) is one of the most common malignant lymphoproliferative diseases. Chemotherapy and radiotherapy used in the treatment of LH induce a number of toxic effects leading to dysfunction of endocrine system. Hormonal disorders in HL and their relationships with the therapy used remain to be clarified. To assess disorders of the endocrine function of thyroid, parathyroid glands and gonads in HL survivors. Screening of endocrine dysfunction of the thyroid, parathyroid glands and gonads was performed in 160 adult patients with HL, 55 men and 105 women, at remission stage induced by chemotherapy or chemoradiotherapy. Forty healthy subjects, matched by age, were acted as control. The levels of TSH, T3, free T4, PTH, FSH, LH, free testosterone, dehydroepiandrosterone sulfate (DHEA-S), and sex-hormone binding globulin (SHBG) were measured in blood serum by ELISA. Bone mineral density (BMD) was assessed by DEXA. Hypothyroidism (25%), hyperparathyroidism (15.6%) and hypogonadism (29% of men and 25.3% of women) were the most prevalent endocrine disorders in LH survivors. Hypothyroidism was significantly more common in patients after chemoradiotherapy than in those who received only chemotherapy (χ2=9.4, р=0.002). In patients with hyperparathyroidism, there were negative correlations between PTH levels and BMD in the lumbar spine (r=-0.74, p=0.00002) and in the femoral neck (r=-0.66, p=0.0003). Men with HL demonstrated lower free testosterone concentrations when compared to control (p=0.04); LH and FSH levels were elevated (p=0.0004 and p=0.04, respectively). In men with HL the levels of DHEA-S were reduced (p=0.0009). The increased SHBG concentrations were revealed in 13 (23.6%) men. Women of reproductive age with HL had higher levels of LH in the luteal phase (p=0.05) and FSH in the follicular phase (p=0.02) than controls. The data indicate a high prevalence of the dysfunctions of thyroid, parathyroid glands, and gonads in HL survivors. Screening for endocrine disorders in these patients is highly recommended.
Sections du résumé
BACKGROUND
BACKGROUND
Hodgkin's lymphoma (HL) is one of the most common malignant lymphoproliferative diseases. Chemotherapy and radiotherapy used in the treatment of LH induce a number of toxic effects leading to dysfunction of endocrine system. Hormonal disorders in HL and their relationships with the therapy used remain to be clarified.
AIM
OBJECTIVE
To assess disorders of the endocrine function of thyroid, parathyroid glands and gonads in HL survivors.
MATERIALS AND METHODS
METHODS
Screening of endocrine dysfunction of the thyroid, parathyroid glands and gonads was performed in 160 adult patients with HL, 55 men and 105 women, at remission stage induced by chemotherapy or chemoradiotherapy. Forty healthy subjects, matched by age, were acted as control. The levels of TSH, T3, free T4, PTH, FSH, LH, free testosterone, dehydroepiandrosterone sulfate (DHEA-S), and sex-hormone binding globulin (SHBG) were measured in blood serum by ELISA. Bone mineral density (BMD) was assessed by DEXA.
RESULTS
RESULTS
Hypothyroidism (25%), hyperparathyroidism (15.6%) and hypogonadism (29% of men and 25.3% of women) were the most prevalent endocrine disorders in LH survivors. Hypothyroidism was significantly more common in patients after chemoradiotherapy than in those who received only chemotherapy (χ2=9.4, р=0.002). In patients with hyperparathyroidism, there were negative correlations between PTH levels and BMD in the lumbar spine (r=-0.74, p=0.00002) and in the femoral neck (r=-0.66, p=0.0003). Men with HL demonstrated lower free testosterone concentrations when compared to control (p=0.04); LH and FSH levels were elevated (p=0.0004 and p=0.04, respectively). In men with HL the levels of DHEA-S were reduced (p=0.0009). The increased SHBG concentrations were revealed in 13 (23.6%) men. Women of reproductive age with HL had higher levels of LH in the luteal phase (p=0.05) and FSH in the follicular phase (p=0.02) than controls.
CONCLUSION
CONCLUSIONS
The data indicate a high prevalence of the dysfunctions of thyroid, parathyroid glands, and gonads in HL survivors. Screening for endocrine disorders in these patients is highly recommended.
Identifiants
pubmed: 37448267
doi: 10.14341/probl13124
pmc: PMC10204787
doi:
Substances chimiques
Testosterone
3XMK78S47O
Follicle Stimulating Hormone
9002-68-0
Dehydroepiandrosterone
459AG36T1B
Types de publication
English Abstract
Journal Article
Langues
rus
Sous-ensembles de citation
IM
Pagination
16-23Références
CA Cancer J Clin. 2018 Sep;68(5):377-386
pubmed: 30240520
Int J Radiat Oncol Biol Phys. 2018 Jul 1;101(3):530-540
pubmed: 29681481
Cell Mol Life Sci. 2019 Feb;76(4):699-728
pubmed: 30377700
JNCI Cancer Spectr. 2019 Apr 09;3(1):pkz008
pubmed: 31360893
Anticancer Res. 2017 Jun;37(6):3035-3043
pubmed: 28551642
Biomed Res Int. 2015;2015:485071
pubmed: 25705661
Cancer Chemother Pharmacol. 2017 Nov;80(5):895-907
pubmed: 28730291
Probl Endokrinol (Mosk). 2021 Jan 08;67(1):31-40
pubmed: 33586390
Acta Haematol. 2004;112(3):148-51
pubmed: 15345897
Clin Adv Hematol Oncol. 2015 Feb;13(2):103-12
pubmed: 25774480
J Adv Pract Oncol. 2015 Mar-Apr;6(2):99-106
pubmed: 26649243
Chemotherapy. 2019;64(1):36-41
pubmed: 31117081
J Clin Densitom. 2013 Jan-Mar;16(1):33-9
pubmed: 23374739